HENDERSON MICHAEL THOMAS 4

What Happened

Michael T. Henderson, CEO of Apogee Therapeutics (APGE), sold a total of 20,000 common shares in open-market transactions on April 8, 2026, for aggregate proceeds of approximately $1,651,664. The sales consisted of 17,800 shares at a reported weighted average price of $82.48 (F2) for $1,468,144; 2,000 shares at a reported weighted average price of $83.26 (F3) for $166,520; and 200 shares at $85.00 for $17,000. These were dispositions (sales), not purchases.

Key Details

• Transaction date: 2026-04-08; Form 4 filed: 2026-04-10 (appears timely).
• Trade details:
  • 17,800 shares sold — reported $82.48 weighted avg; prices ranged $82.00–$82.97 (F2) — $1,468,144.
  • 2,000 shares sold — reported $83.26 weighted avg; prices ranged $83.00–$83.50 (F3) — $166,520.
  • 200 shares sold — $85.00 — $17,000.
• Total: 20,000 shares sold for $1,651,664.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted Aug 13, 2025 (F1). F2 and F3 note weighted-average pricing and per-price ranges; the reporting person can provide per-price counts on request.

Context

• Sales under a Rule 10b5-1 plan are typically prearranged, which can indicate the trades were scheduled in advance rather than reflecting new private information. This is a routine insider sale rather than a purchase (which investors often view as a stronger bullish signal).